Arbutus Biopharma Files 8-K
Ticker: ABUS · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financial-reporting
TL;DR
Arbutus Biopharma filed an 8-K on Oct 15, 2024, updating corporate and financial info.
AI Summary
Arbutus Biopharma Corporation filed an 8-K on October 15, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceuticals Corp, is incorporated in British Columbia, Canada, and its principal executive offices are located in Warminster, Pennsylvania.
Why It Matters
This filing provides an update on Arbutus Biopharma's corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant corporate events or financial updates without immediate market-moving news.
Key Players & Entities
- Arbutus Biopharma Corporation (company) — Registrant
- Tekmira Pharmaceuticals Corp (company) — Former company name
- October 15, 2024 (date) — Date of report
- Warminster, Pennsylvania (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of October 15, 2024.
When was Arbutus Biopharma Corporation incorporated?
Arbutus Biopharma Corporation was incorporated in British Columbia, Canada.
What is the company's principal executive office address?
The company's principal executive offices are located at 701 Veterans Circle, Warminster, Pennsylvania 18974.
Has Arbutus Biopharma Corporation undergone any name changes?
Yes, the company was formerly known as TEKMIRA PHARMACEUTICALS Corp, with name changes recorded on June 7, 2011, and October 3, 2008.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 98-0597776.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-10-15 08:26:48
Filing Documents
- f8k_101524.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-005618.txt ( ) — 222KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_101524_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On October 15, 2024, Arbutus Biopharma Corporation ("Arbutus" or the "Company") issued a press release announcing that clinical data with imdusiran, an RNAi therapeutic, will be highlighted in four poster presentations at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2024, scheduled from November 15-19, 2024 in San Diego, CA. This includes two late-breaking posters with imdusiran data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated October 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: October 15, 2024 By: /s/ David C. Hastings David C. Hastings Chief Financial Officer